Enhancement of proteasome activity by a small-molecule inhibitor of USP14 - PubMed (original) (raw)

. 2010 Sep 9;467(7312):179-84.

doi: 10.1038/nature09299.

Min Jae Lee, Soyeon Park, Dong-Chan Oh, Suzanne Elsasser, Ping-Chung Chen, Carlos Gartner, Nevena Dimova, John Hanna, Steven P Gygi, Scott M Wilson, Randall W King, Daniel Finley

Affiliations

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

Byung-Hoon Lee et al. Nature. 2010.

Abstract

Proteasomes, the primary mediators of ubiquitin-protein conjugate degradation, are regulated through complex and poorly understood mechanisms. Here we show that USP14, a proteasome-associated deubiquitinating enzyme, can inhibit the degradation of ubiquitin-protein conjugates both in vitro and in cells. A catalytically inactive variant of USP14 has reduced inhibitory activity, indicating that inhibition is mediated by trimming of the ubiquitin chain on the substrate. A high-throughput screen identified a selective small-molecule inhibitor of the deubiquitinating activity of human USP14. Treatment of cultured cells with this compound enhanced degradation of several proteasome substrates that have been implicated in neurodegenerative disease. USP14 inhibition accelerated the degradation of oxidized proteins and enhanced resistance to oxidative stress. Enhancement of proteasome activity through inhibition of USP14 may offer a strategy to reduce the levels of aberrant proteins in cells under proteotoxic stress.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Usp14 is an inhibitor of the proteasome

a, Ub-AMC hydrolysis assay of Usp14 activity in the presence or absence of Ub-VS treated human proteasome (VS-proteasome; 1 nM). RFU, relative fluorescence units. Ptsm, 26S proteasome. b, In vitro degradation assay with polyubiquitinated cyclin B (Ubn-ClnB), human proteasome (4 nM), and wild-type Usp14 (Usp14-wt) or mutant Usp14-CA (60 nM). Samples in b, c, and e-h analyzed by SDS-PAGE/immunoblotting (IB). c, Plasmids expressing Tau, TDP-43Flag, or LacZV5 were cotransfected into _usp14_−/− MEFs with variants of Usp14Flag as indicated. Samples collected 2 days post-transfection. Actin, load control. d, Diagram of human Usp14, showing ubiquitin-like (UBL) and catalytic (CAT) domains. C114, active site cysteine. Splice variant Usp14-SF is produced from an mRNA lacking exon 4 (ref 12). e, Flag-tagged Ataxin3-Q22 or -Q80 was coexpressed with Usp14 variants in _usp14_−/− MEFs and detected with anti-Flag antibodies. f, Arg-GFP or control Met-GFP coexpressed with Usp14 variants in _usp14_−/− MEFs. g, As c except in HEK293 cells. h, Usp14-SF associates with but is not activated by proteasomes. Each variant of Usp14Flag was expressed in HEK293T cells containing tagged hRpn11, and proteasomes were affinity purified. Where indicated, Ub-VS was incubated with lysate prior to proteasome purification. Extract samples represent 5% of total. Asterisks, nonspecific signals. Proteasome subunit Rpn13, load control. Control samples, empty vector. Equal cell numbers were used for each lane.

Figure 2

Figure 2. IU1 inhibits human Usp14 specifically and reversibly

a, Chemical structures of IU1 and IU1C. Analytical data shown in Supplementary Fig. 16. b, IC50 determination for IU1 inhibition of Ub-AMC hydrolysis by proteasome-bound Usp14 (4.7 ± 0.7 μM), IsoT (100 ± 0.4μM), and Uch37 (0.7 ± 0.3 mM). c, Ub-AMC (1 μM) hydrolysis assays showing specificity of IU1 for Usp14. d, Reversibility of Usp14 inhibition. 60 nM Usp14 and 5 nM human proteasome were treated with vehicle (DMSO) or 100 μM IU1 for 2 hr. After spin gel-filtration, proteins were assayed for Ub-AMC hydrolysis. All values are presented as mean ± s.d. (n=3).

Figure 3

Figure 3. IU1 inhibits chain trimming and stimulates substrate degradation in vitro

a, Chain trimming assays. Samples contained 4 nM proteasome, and Usp14 was added at 15-fold molar excess over proteasome. IU1 was added at 50 μM and proteasome inhibitors (PI) at 5 μM (PS-341, epoxomicin). Asterisk, cyclin B species derived from residual thrombin from Usp14 preparation. All panels, SDS-PAGE/immunoblot analysis. b, In vitro Ubn-ClnB degradation assay (IU1 at 34 μM). c, In vitro degradation assay with polyubiquitinated Sic1PY, human proteasome (5 nM), and Usp14-wt (75 nM) in the absence or presence of IU1 (75 μM).

Figure 4

Figure 4. IU1 enhances proteasomal degradation in vivo

All panels show SDS-PAGE/immunoblot data. a, 36 hours after cotransfecting wild-type MEFs with plasmids expressing Tau and LacZV5, cells were incubated with 0, 25, 50, 75, or 100 μM of IU1 for 6 hr. LacZ, transfection control. Actin, loading control. b, As in a except that MEFs were _usp14_−/− and IU1 was at 0, 10, 50, or 100 μM. c, Tau and Ub-independent proteasome substrate cODC-EGFP were coexpressed in wild-type MEFs and incubated with 50 μM IU1 for 6hr. Proteasome inhibitors were MG132 (30 μM) and PS-341 (10μM). d, As b except with Atx3-Q80 and Atx3-Q22. e, TDP-43Flag was cotransfected with a LacZ-expressing plasmid into either wild-type or _usp14_−/− MEFs, then treated with IU1 (75 μM) for the time indicated. Asterisk, nonspecific signal. f, HA-tagged Ub and/or Flag-tagged TDP-43 were transiently overexpressed in wild-type MEFs with 50μM IU1 incubation for 6 hr. Proteasome inhibitors (20 μM MG132, 10 μM PS-341) were added 4 hr before lysis. Lysates were subjected to immunoprecipitation with anti-HA or anti-Flag. Arrows indicate likely ubiquitinated TDP-43 species. HC, heavy chain. g, Wild-type MEF and _usp14_−/− MEF cells were treated with IU1 (0, 25, 50, 75, or 100 μM) for 6 hr, followed by analysis for ubiquitin, actin, CP subunit α7, and RP subunit Rpt5.

Figure 5

Figure 5. IU1 alleviates cytotoxicity induced by oxidative stress

a, HEK293 cells were preincubated with IU1 (75 μM) or proteasome inhibitors (20 μM MG132, 10 μM PS-341) for 4 hr, then treated with menadione (300 μM) for 60 min. Lysates were treated with DNPH and immunoblotted with anti-DNP antibody to assay oxidized proteins. b, Cell survival under oxidative stress measured using the MTT assay. HEK293 cells were pretreated with 50 μM IU1 for 2 hr. Menadione was added, followed by 4-hr incubation. IU1 effects comparable to those of panels a and b were obtained in wild-type but not _usp14_−/− MEFs (data not shown). Values are represented as mean ± s.d. (n=3).

Similar articles

Cited by

References

    1. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 2009;78:477–513. - PMC - PubMed
    1. Schrader EK, Harstad KG, Matouschek A. Targeting proteins for degradation. Nat Chem Biol. 2009;5:815–822. - PMC - PubMed
    1. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000;19:94–102. - PMC - PubMed
    1. Verma R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298:611–615. - PubMed
    1. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature. 2002;419:403–407. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources